5-{5-acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}pyridine-2-carbonitrile | 675103-35-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-{5-acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}pyridine-2-carbonitrile
• 英文别名: 5-{5-acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyrimidinyl}-2-pyridinecarbonitrile；BAY-678 racemate；5-[5-acetyl-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-6-yl]pyridine-2-carbonitrile
• CAS: 675103-35-2
• 化学式: C₂₀H₁₅F₃N₄O₂
• 分子量: 400.36
• InChiKey: PGIVGIFOWOVINL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  86.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-{5-acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}pyridine-2-carbonitrile 在 chiral silica gelphase based on the monomer selector N-methacryloyl-L-leucine-1-menthylamide 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 生成 5-[(4R)-5-乙酰基-1,2,3,4-四氢-6-甲基-2-氧代-1-[3-(三氟甲基)苯基]-4-嘧啶基]-2-吡啶腈
  参考文献：
  名称：

  冻结生物活性构象以增强效能：BAY 85-8501的鉴定，BAY 85-8501是人类中性粒细胞弹性蛋白酶对肺部疾病的选择性和强效抑制剂

  摘要：

  Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors

  DOI：

  10.1002/cmdc.201500131
• 作为产物：
  描述：

  3-(三氟甲基)苯硫脲 、 5-甲酰基吡啶-2-甲腈 、 乙酰丙酮 在 polyphosphoric acid ethyl ester 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以44%的产率得到5-{5-acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}pyridine-2-carbonitrile
  参考文献：
  名称：

  冻结生物活性构象以增强效能：BAY 85-8501的鉴定，BAY 85-8501是人类中性粒细胞弹性蛋白酶对肺部疾病的选择性和强效抑制剂

  摘要：

  Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors

  DOI：

  10.1002/cmdc.201500131

文献信息

• [EN] PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES<br/>[FR] DERIVES DE PYRIMIDINONE UTILISES COMME AGENTS THERAPEUTIQUES CONTRE DES PROCESSUS INFLAMMATOIRES, ISCHEMIQUES ET DE REMODELAGE AIGUS ET CHRONIQUES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004024700A1

  公开（公告）日：2004-03-25

  The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases.

  这项发明涉及新颖的杂环衍生物，其制备方法以及它们在药物中的应用，特别是用于慢性阻塞性肺疾病的治疗。
• Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
  申请人：Gielen-Haertwig Heike

  公开号：US20060160801A1

  公开（公告）日：2006-07-20

  The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases.

  该发明涉及新型杂环衍生物，其制备方法以及在药物中的应用，特别是用于慢性阻塞性肺疾病的治疗。
• Heterocyclic Derivatives
  申请人：Gielen-Haertwig Heike

  公开号：US20080021053A1

  公开（公告）日：2008-01-24

  The invention relates to novel heterocyclic derivatives of the general formula (I), processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

  本发明涉及一种新型杂环衍生物，其通式为(I)，其制备方法以及它们在药物中的应用，特别是用于慢性阻塞性肺疾病、急性冠状动脉综合症、急性心肌梗死和心力衰竭的治疗。
• HETEROCYCLIC DERIVATIVES
  申请人：GIELEN-HAERTWIG Heike

  公开号：US20100184788A1

  公开（公告）日：2010-07-22

  The invention relates to novel heterocyclic derivatives of the general formula (I), processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, and heart failure development.

  该发明涉及一种新的杂环衍生物，其一般式为(I)，以及制备它们的过程和它们在药物中的应用，特别是用于治疗慢性阻塞性肺疾病、急性冠状动脉综合征、急性心肌梗死和心力衰竭的发展。
• Heterocyclic derivatives
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：US07893073B2

  公开（公告）日：2011-02-22

  The invention relates to novel 3,4-dihydropyrimidin-2(1H)-one derivatives having the formula processes for their preparation, and their use in compositions, and in the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

  本发明涉及一种新型3，4-二氢嘧啶-2（1H）-酮衍生物，其具有以下结构式：以及制备它们的方法，以及它们在组合物中的应用，以及在治疗慢性阻塞性肺疾病、急性冠状动脉综合征、急性心肌梗死和心力衰竭发展中的应用。